EMEA Urology Market Access Director

At Veracyte, we believe exceptional cancer care begins with exceptional diagnostics. Our mission is clear: empower clinicians with high-value insights essential in the race to diagnose and treat various cancers, including thyroid, prostate, breast, bladder, and lung cancers, as well as interstitial lung diseases. Through our rigorous, multi-disciplinary innovation process, we identify unmet clinical needs and develop genomic tests that provide actionable insights to enhance patient care.

Our innovative solutions offer clarity at critical moments during a patient’s cancer care journey, enabling informed decision-making for both clinicians and patients. Veracyte’s tests help avoid unnecessary procedures by ensuring timely and accurate diagnoses. With over 400,000 patients benefiting from our advanced molecular tests, we address the significant global challenge, as more than 7 million people are diagnosed with cancers that our tests target each year. Together with our clinical partners, we aim to elevate the standard of care and make leading diagnostics accessible worldwide, embodying our vision of transforming cancer care for patients globally.